BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings

Reuters01-30
BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings

** Shares of drugmaker Corcept Therapeutics CORT.O fall 16.5% to $37.25 premarket

** Last year, the U.S. FDA declined to approve Corcept's drug application for relacorilant to treat hypertension in Cushing's syndrome patients

** FDA had warned Corcept "on several occasions" about concerns with the clinical program and to "expect significant review issues" if they submitted, the regulator's letter dated January 28 showed

** UBS analyst Ashwani Verma said the letter was made public on the FDA's website on Thursday around 4 pm E.T.

** Corcept has one year to conduct new clinical trials or the application may be withdrawn, the letter stated

** The original CRL was dated December 30, 2025, and this January 28 version is a corrected version issued in response to communications from Corcept, the letter showed

** The company did not immediately respond to Reuters request for comment

** CORT fell 30.9% in 2025

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment